Report
Thomas Vranken

Mithra Dismantling process initiated

Mithra initiates the process to monetise its assets or sell its business with a 60-day bridge loan facility to fund the process. The appointment of CEO David H. Solomon was terminated, while CFO and COO take over as co-CEOs.
Underlying
N.V. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities
Jacob Mekhael ... (+5)
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Sharad Kumar S.P
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch